Close Menu

Agilent

Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.

The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.

With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.

The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.

The firm's diagnostics and genomics group saw a 5 percent year-over-year revenue increase in the fourth quarter.

Under a collaboration agreement, the firms plan to put together Agilent's SLIMS laboratory information system and MGI's DNBSeq series of sequencing platforms.

The company said it will use the funds to support development of its structure for lossless ion manipulation (SLIM) ion mobility separations technology.

Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.